579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)

• DOI: 10.1016/j.annonc.2021.08.1092
• Publication Date: 2021-09-21T18:58:05Z
• Authors: D.P. Petrylak; J.L. Perez-Gracia; L. Lacombe; D.A. Bastos; H. Mahammedi; E.M. Kwan; S. Zschäbitz; A.J. Armstrong; R.K. Pachynski; J.C. Goh; M. Burotto; G. Gravis; S.L. McCune; J.C. Vázquez Limón; M. Retz; F. Saad; N.P. Amin; J. Li; K. Unsal-Kacmaz; K. Fizazi
• Keywords: Enzalutamide